Scarica l'app Stockscreener
2.40
0.00%
0.00
Neuraxis Inc Borsa (NRXS) Ultime notizie
FDA Approvals News Live Feed - StockTitan
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com
Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire
NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan
FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag
Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com
Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa
Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria
Neuraxis secures $5 million in preferred stock sale - Investing.com
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartzy
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
NeurAxis (NRXS) Sets Q3 2024 Earnings Call for November 12 | Neuromodulation Leader | NRXS Stock News - StockTitan
IRIDEX (NASDAQ:IRIX) versus NeurAxis (NASDAQ:NRXS) Financial Survey - Defense World
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 - The Manila Times
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation - GlobeNewswire
Neuraxis adjusts equity agreement, secures additional funding - Investing.com India
Creatd (NASDAQ:VOCL) Stock Price Down 4.4% – Should You Sell? - Defense World
Technip Energies (OTCMKTS:THNPY) Trading Up 0.7% – Here’s What Happened - Defense World
Vestas Wind Systems A/S (OTCMKTS:VWSYF) Shares Up 1.2% – Here’s What Happened - Defense World
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
2.88%
2.65%
Capitalizzazione:
|
Volume (24 ore):